Get the Stockscreener App
0.5564
0.51%
0.0028
After Hours:
.55
-0.0064
-1.15%
Vyne Therapeutics Inc stock is traded at $0.5564, with a volume of 390.15K.
It is up +0.51% in the last 24 hours and up +50.38% over the past month.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
See More
Previous Close:
$0.5536
Open:
$0.55
24h Volume:
390.15K
Relative Volume:
0.07
Market Cap:
$18.52M
Revenue:
$476.00K
Net Income/Loss:
$-38.52M
P/E Ratio:
-0.6154
EPS:
-0.9041
Net Cash Flow:
$-39.89M
1W Performance:
-4.09%
1M Performance:
+50.38%
6M Performance:
-56.87%
1Y Performance:
-87.00%
1-Day Range:
$0.5495
$0.5656
1-Week Range:
$0.5495
$0.5801
52-Week Range:
$0.2805
$4.30
Vyne Therapeutics Inc Stock (VYNE) Company Profile
Name
Vyne Therapeutics Inc
Sector
Industry
Phone
800-775-7936
Address
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
Compare VYNE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VYNE
Vyne Therapeutics Inc
|
0.5564 | 18.43M | 476.00K | -38.52M | -39.89M | -0.9041 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-25 | Downgrade | BTIG Research | Buy → Neutral |
| Nov-18-24 | Initiated | BTIG Research | Buy |
| Dec-06-21 | Resumed | H.C. Wainwright | Buy |
Vyne Therapeutics Inc Stock (VYNE) Latest News
What insider trading reveals about VYNE Therapeutics Inc. stockRisk Mitigation Techniques & Free ETF and Mutual Fund Comparisons - ulpravda.ru
VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Down 18.2% in December - Defense World
VYNE Therapeutics Inc. (VYNE) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
VYNE SEC FilingsVyne Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Vyne Therapeutics shares surge on merger deal with Yarrow Bioscience - MSN
Why VYNE Therapeutics Inc. stock remains resilient2025 EndofYear Setup & Entry Point Confirmation Signals - Улправда
VYNE Therapeutics to merge with Yarrow Bioscience, secures $200M financing; shares up - MSN
Halper Sadeh LLC Encourages FOLD, VYNE, HTBK, FMNB Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
Halper Sadeh LLC Encourages FOLD, VYNE, HTBK, FMNB Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
How VYNE Therapeutics Inc. stock compares to industry benchmarksMarket Sentiment Review & AI Enhanced Market Trend Forecasts - Улправда
Should I hold or sell VYNE Therapeutics Inc. stock in 2025Market Activity Summary & High Conviction Trade Alerts - Улправда
Is VYNE Therapeutics Inc. stock resilient to inflation2025 Market Outlook & AI Based Buy and Sell Signals - Улправда
Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders - PR Newswire
Risk Analysis: Will VYNE Therapeutics Inc. stock benefit from automation2025 Buyback Activity & Real-Time Volume Surge Alerts - Улправда
3 Penny Stocks to Watch Now, 12/18/25 - TipRanks
3 penny stocks to watch now, 12/18/25 - MSN
VYNE Therapeutics to merge with Yarrow Bioscience in $200 million deal - Investing.com
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE) - PR Newswire
VYNE Therapeutics Inc. (VYNE) Stock: Soars 55.45% on Merger Announcement with Yarrow Bioscience - parameter.io
Roundup: Harbor BioMed Announces Collaboration and License Agreement with Bristol Myers, Squibb, VYNE Therapeutics Enters Merger Agreement with Yarrow Bioscience - PharmExec.com
VYNE Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of VYNE Therapeutics Inc. is Fair to Shareholders - The AI Journal
VYNE Therapeutics: A New Chapter in Autoimmune Disease with Yarrow Bioscience - FinancialContent
Transcript : VYNE Therapeutics Inc., Yarrow Bioscience, Inc.M&A Call - marketscreener.com
VYNE Therapeutics (VYNE) Surges on Merger with Yarrow Bioscience - GuruFocus
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Crude Oil Rises Over 1%; General Mills Earnings Top Views - Benzinga
Yarrow Bioscience, Inc. entered into an Agreement and Plan of Merger and Reorganization to acquire VYNE Therapeutics Inc. in a reverse merger transaction. - marketscreener.com
VYNE: VYNE and Yarrow merge to advance YB-101 for Graves' disease and TED, backed by $200M funding - TradingView — Track All Markets
Dow Jumps 150 Points; Jabil Posts Upbeat Earnings - Benzinga
Vyne Therapeutics stock soars after merger with Yarrow Bioscience By Investing.com - Investing.com Nigeria
Vyne Therapeutics stock soars after merger with Yarrow Bioscience - Investing.com
VYNE Announces Merger with Yarrow Bioscience, Focuses on TSHR An - GuruFocus
VYNE Therapeutics Announces Merger with Yarrow Bioscience - TipRanks
VYNE Therapeutics, Yarrow Bioscience enter merger agreement - TipRanks
Vyne Therapeutics and Yarrow Bioscience announce merger agreement - marketscreener.com
VYNE FinancialsIncome Statement - Quiver Quantitative
VYNE and Yarrow Bioscience to merge in all-stock transaction - Investing.com
VYNE Therapeutics (VYNE) plans merger with Yarrow, Yarrow to own 97% - Stock Titan
VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement - marketscreener.com
VYNE Therapeutics Inc Stock Analysis and ForecastPrice Action Trading & Backtest Your Strategy Before You Risk Money - earlytimes.in
[Form 4] VYNE Therapeutics Inc. Insider Trading Activity - Stock Titan
VYNE Therapeutics (VYNE) director reports annual 20,000 option grant - Stock Titan
VYNE Therapeutics (VYNE) reports 20,000 stock options granted to director - Stock Titan
Is it possible to buy VYNE Therapeutics Inc(VYNE) shares at a good price now? - uspostnews.com
VYNE Therapeutics Approves Director Elections and Proposals - The Globe and Mail
[8-K] VYNE Therapeutics Inc. Reports Material Event | VYNE SEC FilingForm 8-K - Stock Titan
VYNE Therapeutics Inc (VYNE) Performance and Fundamentals Dashboard tells a completely different story - setenews.com
Can VYNE Therapeutics Inc. stock resist sector downturnsTrade Exit Summary & Low Risk Profit Maximizing Plans - Newser
VYNE Therapeutics (VYNE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Vyne Therapeutics Inc Stock (VYNE) Financials Data
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):